Pharmaceutical industry haunted by support for government health care

Published



Drug makers are under fire as the $84,000 price tag on a new hepatitis medicine has galvanized the debate over prescription drug costs. But the pharmaceutical industry could be mounting a much stronger defense if it weren’t haunted by its support for government health care.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.